Further evidence for a coexistence of FAS and FAO was provided by the fact that simultaneous targeting of FAS and FAO resulted in enhanced therapeutic effects in prostate cancer [18] and myeloma [19]. The gene discussed is FAS; the disease is plasma cell myeloma.